Shkreli’s lifetime ban upheld

Martin Shkreli cannot return to the pharmaceuticals industry because his illegal monopolisation of a HIV medicine threatened lives and is likely to reoccur, a federal appellate court has ruled.

Unlock unlimited access to all Global Competition Review content